Added diagnostic value of digital PET-CT in (re)staging of patients with (borderline) resectable pancreatic cancer treated with neo-adjuvant chemo(radio)therapy.
(side-studie van de Preopanc-2 trial).
Deelnemende centra: Isala, LUMC
Hoofdonderzoekers: G. Patijn, chirurg, Isala (PI); P. Jager, Isala; A. Vahrmeijer, LUMC; L.-F. de Geus-Oei, LUMC.
Inclusies: Gestart september 2018. Update april 2020: 20/40 (50%) geincludeerd.
Rationale: For pancreatic cancer, surgery is the only treatment method that can potentially cure the patient. Currently only 20% of the patients are eligible for a surgical resection with curative intent. Neo-adjuvant (radio)chemotherapy has shown promising clinical results¹. Currently, contrast-enhanced Computed Tomography scans (ceCT) of the abdomen is routinely used for (re)staging of pancreatic cancer.
Response evaluation with ceCT scans is however unreliable, because it is not possible to distinguish between post-treatment fibrosis and viable tumor tissue.
A novel digital PET/CT-system was recently introduced in Isala and LUMC, which provides PET images that are significantly more detailed and accurate when compared to the analog PET systems (see image below).
Objective: Assess the diagnostic value of digital PET/CT as a staging and restaging imaging modality as compared with the standard ceCT, in patients with (borderline) resectable pancreatic cancer, who are treated with neo-adjuvant therapy before surgery.
Study design: Multi-center diagnostic accuracy study using intra-individual comparisons of FDG-PET/CT and ceCT.
Study population: 40 adults with (borderline) resectable pancreatic cancer in Isala and LUMC, who are treated with neo-adjuvant (radio)chemotherapy in the PREOPANC-2 trial.
Main study parameters: Diagnostic value (sensitivity, specificity, accuracy) of digital PET/CT for staging and response assessment.